AtriCure, Inc.

ATRC • Medical - Instruments & Supplies

$51.52

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$2.53B

Growth

33.3%

Cash Flow

1/5

Trend

Volatile

Evidence

Positive revenue growth · 16.5%Positive free cash flow · 1.01Manageable debt level · 0.18Healthy liquidity · 3.96Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$51.52

Change0.00%

Shares Out49.09M

Market Cap$2.53B

Enterprise Value$2.42B

52W Range25.36 - 43.18

Beta1.25

P/E239.70

P/S4.44

P/B4.90

P/FCF47.62

EV/Sales4.25

Price$51.52

Change0.00%

Shares Out49.09M

Market Cap$2.53B

Enterprise Value$2.42B

52W Range25.36 - 43.18

Beta1.25

P/E239.70

P/S4.44

P/B4.90

P/FCF47.62

EV/Sales4.25

EV/EBITDA93.38

EV/FCF45.61

Earnings Yield0.42%

FCF Yield2.10%

Dividend Yield0.00%

Gross Margin74.41%

Oper. Margin-0.64%

Profit Margin-2.14%

Debt/Eq0.18

Current Ratio3.96

Quick Ratio2.99

Revenue 5Y33.29%

Target$56.00

Target Upside8.70%

Target Median$55.00

Target Range50.00 - 64.00

Volume1.04M

Avg Volume930.62K

EPS Surprise0.07

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

49/100

Why this score▼

Positive revenue growth · 16.5%Positive free cash flow · 1.01Manageable debt level · 0.18Healthy liquidity · 3.96Weak profitability

Analyst view

Analyst sentiment and price target

ATRC

Analyst sentiment

Based on 19 analyst votes · 2026-09-05

97/100

Bullish

Hold

Bearish

Price Target

2026-07-29

Low

$44.00

Mean

$50.25

Median

$51.00

High

$55.00

Company Overview

IPO: 8/5/2005

Industry: Medical - Instruments & Supplies

P/B i: 4.90

Debt / Equity i: 0.18

Operating Margin: -0.64%

Net Margin: -2.14%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.18

Current Ratio: 3.96

Quick Ratio: 2.99

Status: Good

Insider Transactions

Recent executive and insider activity

Privitera Salvatore

Transaction: 06/30/2026

BUY

Change

+636

Price

$23.78

Filing

07/02/2026

Type

BUY

Seith Douglas J

Transaction: 06/30/2026

BUY

Change

+527

Price

$23.78

Filing

07/02/2026

Type

BUY

Dahlquist Karl S.

Transaction: 06/30/2026

BUY

Change

+636

Price

$23.78

Filing

07/02/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Privitera Salvatore	BUY	+636	$23.78	06/30/2026	07/02/2026
Seith Douglas J	BUY	+527	$23.78	06/30/2026	07/02/2026
Dahlquist Karl S.	BUY	+636	$23.78	06/30/2026	07/02/2026
Doraiswamy Vinayak	BUY	+636	$23.78	06/30/2026	07/02/2026
CARREL MICHAEL H	BUY	+636	$23.78	06/30/2026	07/02/2026
Prange Karen	SELL	-3,000	$28.65	05/20/2026	05/22/2026
WHITE ROBERT S.	BUY	+6,144	Not reported	05/18/2026	05/20/2026
WEHRWEIN SVEN	BUY	+6,144	Not reported	05/18/2026	05/20/2026
GROVES REGINA E	BUY	+6,144	Not reported	05/18/2026	05/20/2026
JOHNSON B KRISTINE	BUY	+6,144	Not reported	05/18/2026	05/20/2026
Nachman Shlomo	BUY	+6,144	Not reported	05/18/2026	05/20/2026
Yuen Maggie	BUY	+6,144	Not reported	05/18/2026	05/20/2026
Telman Deborah H	BUY	+6,144	Not reported	05/18/2026	05/20/2026
Prange Karen	BUY	+6,144	Not reported	05/18/2026	05/20/2026
Doraiswamy Vinayak	SELL	-5,000	$28.13	05/15/2026	05/18/2026
Doraiswamy Vinayak	SELL	-5,000	$29.83	03/12/2026	03/16/2026
WHITE ROBERT S.	SELL	-10,000	$14.99	03/10/2026	03/12/2026
WHITE ROBERT S.	BUY	+10,000	$14.99	03/10/2026	03/12/2026
CARREL MICHAEL H	SELL	-1,000	Not reported	03/06/2026	03/09/2026
Dahlquist Karl S.	SELL	-15,687	$31.26	03/01/2026	03/03/2026

About the Company

AtriCure, Inc.

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.

Source - link

Peers

AZTA BLFS IMCR KMTS LMAT NVCR QDEL SEM TXG XERS

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Zacks Investment Research

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties may a.

Business Wire

AtriCure: Promising Cardiovascular Surgical Platform

AtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.

Seeking Alpha

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.

MarketBeat

A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95

On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a strong performance in the market. Over the past week, the s

GuruFocus

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-05	-0.07	0.0022	0.0722
2026-02-17	-0.04003	0.06	0.10003
2025-10-29	-0.11	-0.01	0.1
2025-07-29	-0.15	-0.02	0.13
2025-04-29	-0.25	-0.14	0.11
2025-02-12	-0.23	-0.08	0.15
2024-10-29	-0.2	-0.17	0.03
2024-07-30	-0.15	-0.17	-0.02
2024-05-01	-0.21	-0.25	-0.04
2024-02-15	-0.22	-0.21	0.01
2023-11-01	-0.3	-0.2	0.1
2023-07-25	-0.27	-0.12	0.15